New Players on the Scene: Sanofi’s Amlitelimab Shows Promising Efficacy
In Phase 2b trials, Sanofi’s amlitelimab yielded up to 61.5% EASI improvement by week 16, with continued gains into week 24—potentially poised to disrupt treatment norms.
Source: https://www.marketresearchfutu....re.com/reports/atopi
पसंद करना
टिप्पणी
शेयर करना
